436 related articles for article (PubMed ID: 35997897)
1. Therapeutic siRNA: State-of-the-Art and Future Perspectives.
Friedrich M; Aigner A
BioDrugs; 2022 Sep; 36(5):549-571. PubMed ID: 35997897
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticles and siRNA: A new era in therapeutics?
Pérez-Carrión MD; Posadas I; Ceña V
Pharmacol Res; 2024 Mar; 201():107102. PubMed ID: 38331236
[TBL] [Abstract][Full Text] [Related]
3. Small interfering RNA: Discovery, pharmacology and clinical development-An introductory review.
Ranasinghe P; Addison ML; Dear JW; Webb DJ
Br J Pharmacol; 2023 Nov; 180(21):2697-2720. PubMed ID: 36250252
[TBL] [Abstract][Full Text] [Related]
4. siRNA Design and GalNAc-Empowered Hepatic Targeted Delivery.
Lu M; Zhang M; Hu B; Huang Y
Methods Mol Biol; 2021; 2282():77-100. PubMed ID: 33928571
[TBL] [Abstract][Full Text] [Related]
5. RNA interference in the era of nucleic acid therapeutics.
Jadhav V; Vaishnaw A; Fitzgerald K; Maier MA
Nat Biotechnol; 2024 Mar; 42(3):394-405. PubMed ID: 38409587
[TBL] [Abstract][Full Text] [Related]
6. Development of siRNA Therapeutics for the Treatment of Liver Diseases.
Holm A; Løvendorf MB; Kauppinen S
Methods Mol Biol; 2021; 2282():57-75. PubMed ID: 33928570
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic siRNA: state of the art.
Hu B; Zhong L; Weng Y; Peng L; Huang Y; Zhao Y; Liang XJ
Signal Transduct Target Ther; 2020 Jun; 5(1):101. PubMed ID: 32561705
[TBL] [Abstract][Full Text] [Related]
8. The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of
McDougall R; Ramsden D; Agarwal S; Agarwal S; Aluri K; Arciprete M; Brown C; Castellanos-Rizaldos E; Charisse K; Chong S; Cichocki J; Fitzgerald K; Goel V; Gu Y; Guenther D; Habtemariam B; Jadhav V; Janas M; Jayaraman M; Kurz J; Li J; Liu J; Liu X; Liou S; Maclauchlin C; Maier M; Manoharan M; Nair JK; Robbie G; Schmidt K; Smith P; Theile C; Vaishnaw A; Waldron S; Xu Y; Zhang X; Zlatev I; Wu JT
Drug Metab Dispos; 2022 Jun; 50(6):781-797. PubMed ID: 34154993
[TBL] [Abstract][Full Text] [Related]
9. siRNA delivery systems for cancer treatment.
Oh YK; Park TG
Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
[TBL] [Abstract][Full Text] [Related]
10. RNA therapeutics for metabolic disorders.
Vu TD; Lin SC; Wu CC; Chu DT
Prog Mol Biol Transl Sci; 2024; 203():181-196. PubMed ID: 38359998
[TBL] [Abstract][Full Text] [Related]
11. Re-Engineering RNA Molecules into Therapeutic Agents.
Egli M; Manoharan M
Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
[TBL] [Abstract][Full Text] [Related]
12. Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate.
Zimmermann TS; Karsten V; Chan A; Chiesa J; Boyce M; Bettencourt BR; Hutabarat R; Nochur S; Vaishnaw A; Gollob J
Mol Ther; 2017 Jan; 25(1):71-78. PubMed ID: 28129130
[TBL] [Abstract][Full Text] [Related]
13. Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.
Titze-de-Almeida SS; Brandão PRP; Faber I; Titze-de-Almeida R
Mol Diagn Ther; 2020 Feb; 24(1):49-59. PubMed ID: 31701435
[TBL] [Abstract][Full Text] [Related]
14. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
[TBL] [Abstract][Full Text] [Related]
15. [Not Available].
Lemoine S; Courbebaisse M
Nephrol Ther; 2022 Dec; 18(6S1):6S1-6S6. PubMed ID: 36585119
[TBL] [Abstract][Full Text] [Related]
16. Strategies, design, and chemistry in siRNA delivery systems.
Dong Y; Siegwart DJ; Anderson DG
Adv Drug Deliv Rev; 2019 Apr; 144():133-147. PubMed ID: 31102606
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pharmacology of RNA Interference-Based Therapeutics: A Summary Based on Food and Drug Administration-Approved Small Interfering RNAs.
Jing X; Arya V; Reynolds KS; Rogers H
Drug Metab Dispos; 2023 Feb; 51(2):193-198. PubMed ID: 36332914
[TBL] [Abstract][Full Text] [Related]
18. Where should siRNAs go: applicable organs for siRNA drugs.
Ahn I; Kang CS; Han J
Exp Mol Med; 2023 Jul; 55(7):1283-1292. PubMed ID: 37430086
[TBL] [Abstract][Full Text] [Related]
19. Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of
Ayyar VS; Song D; Zheng S; Carpenter T; Heald DL
J Pharmacol Exp Ther; 2021 Nov; 379(2):134-146. PubMed ID: 34413198
[TBL] [Abstract][Full Text] [Related]
20. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
